Medpace Holdings Inc vs Stitch Fix Inc — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while Stitch Fix Inc trades at $2.74 (market cap $366.07M). The key difference: Medpace Holdings Inc is far larger — about 45.9× Stitch Fix Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Stitch Fix Inc for 31 Days on average.
| MEDP | SFIX | |
|---|---|---|
Market Cap | $16.82B | $366.07M |
Volume | 223,093 | 5,152,008 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $5.64 |
52-Week Low | $393.42 | $2.16 |
Typical Hold Time | 14 Days | 31 Days |
Enterprise Value | $16.44B | $261.88M |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Stitch Fix (SFIX) trades at $2.73, up 2.25% on the day, but remains under pressure with a bearish technical signal and weak fundamentals. The company reported a net loss of $28.74 million in fiscal 2025, though revenue stabilized at $1.27 billion. Recent quarterly earnings have beaten expectations, but weak fiscal 2027 guidance and multiple law firm investigations have dampened sentiment. The stock is trading near the low end of analyst price targets, reflecting significant skepticism about near-term prospects.
The outlook for SFIX is challenging, with profitability remaining elusive and revenue growth stagnant. The primary opportunity lies in successful execution of its AI-driven personalization strategy to improve client engagement and margins. Key risks include intense competition, high customer acquisition costs, and the ongoing legal overhangs. Analyst consensus is cautious, with a hold rating predominant, suggesting limited upside until the company demonstrates a sustainable path to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →